A space biotech company hopes its __Salmonella__ vaccine project will pave the way for other lucrative space biotech projects. The company, SPACEHAB, launched its proof-of-concept experiment as part of the space shuttle Discovery's payload on Saturday (May 31). In linkurl:April,;http://www.the-scientist.com/blog/display/54609/ I reported that SPACEHAB's CEO Tom Pickens talked up the potential for space biotech at a Congressional hearing on the future of the linkurl:International Space Station.;http://science.house.gov/press/PRArticle.aspx?NewsID=1928 SPACEHAB is starting with __Salmonella__ vaccine production, Yahoo News linkurl:reported.;http://science.house.gov/press/PRArticle.aspx?NewsID=1928 Research into a __Salmonella__ vaccine has been hampered partly because the bacterium quickly loses virulence on earth, making it difficult to find an appropriate strain for vaccination. However, a linkurl:recent study;http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=17901201 showed that __Salmonella__ becomes more virulent in space , which could help scientists create a linkurl:potent vaccine strain.;http://www.the-scientist.com/news/home/53627/ So researchers are sending up several potential vaccine strains to test which might be the most effective. If the experiment works, other commercial research would...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?